TransCode Therapeutics (RNAZ) Short Interest Ratio & Short Volume

Short interest is the volume of TransCode Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 18,600 shares of RNAZ short. 0.28% of TransCode Therapeutics' shares are currently sold short. Learn More on TransCode Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.28% of TransCode Therapeutics' floating shares are currently sold short.

TransCode Therapeutics saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 18,600 shares, a decline of 53.5% from the previous total of 40,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

TransCode Therapeutics currently has issued a total of 6,110,000 shares. Some of TransCode Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. TransCode Therapeutics currently has a public float of 6,540,000 shares.

0.28% of TransCode Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to TransCode Therapeutics: Atreca, Inc. (0.37%), Revelation Biosciences, Inc. (1.13%), Seelos Therapeutics, Inc. (5.48%), GeoVax Labs, Inc. (0.28%), Phio Pharmaceuticals Corp. (0.75%), Virpax Pharmaceuticals, Inc. (1.70%), Evoke Pharma, Inc. (0.54%), Agile Therapeutics, Inc. (12.68%), ZyVersa Therapeutics, Inc. (6.14%), Soligenix, Inc. (8.00%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks.

Short selling RNAZ is an investing strategy that aims to generate trading profit from TransCode Therapeutics as its price is falling. RNAZ shares are trading up $0.35 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for TransCode Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RNAZ, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RNAZ, twice per month. The most recent reporting period available is April, 15 2024.